Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected stock price increase of over 15% relative to the industry index within the next six months [4][11]. Core Views - The company has shown steady revenue performance in Q3, although profits are slightly under pressure. The revenue for H1 2024 was 350 million yuan, a year-on-year decrease of 5.1%, while the net profit attributable to shareholders was 100 million yuan, an increase of 11.8% year-on-year [1][2]. - The company is experiencing a decline in revenue from major products due to insufficient consumer demand, but the domestic market remains stable. Revenue from key product categories such as Ganoderma lucidum spore powder and Dendrobium officinale has decreased by 6.6% and 6.0% respectively [2]. - The company is actively optimizing its marketing structure and expanding its channels, with the addition of 7 new specialty stores and 14 new channels in the first half of the year. This is expected to enhance product demand in the upcoming peak seasons [2][3]. Financial Summary - For the fiscal year 2022, the company reported a revenue of 829 million yuan, which is projected to decrease to 784 million yuan in 2023, followed by a recovery to 850 million yuan in 2024 [1][5]. - The net profit attributable to shareholders is expected to recover from 254 million yuan in 2023 to 284 million yuan in 2024, with a projected growth rate of 11.7% [1][5]. - The company's gross margin for H1 2024 was 81.3%, a slight decrease of 0.8 percentage points year-on-year, primarily due to reduced scale effects and the impact of new production areas [2][6]. Market and Product Insights - The company’s revenue from the domestic market was 250 million yuan, reflecting a year-on-year growth of 7.4%, while revenue from outside the province and online sales saw significant declines of 24.7% and 26.6% respectively [2]. - The report anticipates stable growth in the traditional Chinese medicine and health products industry, supported by the company's core competitive advantages and ongoing research and innovation efforts [2][3]. Future Projections - The company is expected to achieve net profits of 280 million yuan, 310 million yuan, and 350 million yuan for the years 2024, 2025, and 2026 respectively, with corresponding price-to-earnings ratios of 14, 13, and 11 times [2][3].

浙江寿仙谷医药股份有限公司 2024 年半年度业绩电话交流会会议纪要 一、会议基本情况 （一）会议时间：2024 年 8 月 28 日 15:30-16:30 （二）会议形式：电话会议 （三）公司参会人员及职务： 董事兼总经理李振宇，董事、副总经理兼董事会秘书刘国芳，董事兼副总经理林荣志， 副总经理王汉波，投资者服务部总监曹秀娟 （四）调研机构名称（排名不分先后）： 东吴证券、中邮证券、华鑫证券、申万宏源证券、华福证券、兴业证券、西部证券、东 北证券、德邦证券、华西证券、国元证券、国投证券、上海证券、中原证券、西南证券、光 大证券、国盛证券、中国银河证券、海通证券、中信建投证券、开源证券、华安证券、国联 证券、中信证券、信达证券、浙商证券、天风证券、广发证券、长城证券、招商证券、中银 证券、华创证券等机构。 二、会议交流主要内容 （一）董秘刘国芳介绍公司基本情况及 2024 年半年度经营情况 1、公司基本情况 寿仙谷药号始创于 1909 年，是一家百年传承的中华老字号企业、国家级非物质文化遗 产代表性项目保护单位、国家高新技术企业，全国农业重点龙头企业。2021 年获评浙江省 人民政府质量奖，今年公司为共同完 ...

Financial Performance - The company reported a significant increase in revenue for the first half of 2024, with a year-on-year growth of 25%[2]. - The company's operating revenue for the first half of 2024 was approximately ¥352.59 million, a decrease of 5.09% compared to ¥371.49 million in the same period last year[15]. - Net profit attributable to shareholders of the listed company reached approximately ¥100.87 million, an increase of 11.79% from ¥90.24 million year-on-year[15]. - The net profit after deducting non-recurring gains and losses was approximately ¥85.17 million, reflecting a year-on-year increase of 9.79% from ¥77.58 million[15]. - The net cash flow from operating activities was approximately ¥128.65 million, down 20.19% from ¥161.20 million in the previous year[15]. - The gross profit margin for the main business in the first half of 2024 was 82.96%, down from 84.43% in the same period of 2023[62]. - The company achieved operating revenue of CNY 352.59 million, a decrease of 5.09% year-on-year, while net profit attributable to shareholders increased by 11.79% to CNY 100.87 million[50]. - The company reported a total of 201,828,671 shares outstanding, with no new shares issued during the reporting period[100]. User Growth and Market Expansion - User data indicates a 15% increase in active users compared to the same period last year, reaching a total of 1.2 million users[2]. - The company is expanding its market presence, targeting a 30% increase in distribution channels by the end of 2024[2]. - The company added 7 new specialty stores and 14 new channels, including 4 OTC channels and 8 medical channels, enhancing its market presence[51]. - The company plans to focus on expanding its market presence and enhancing product development in the upcoming quarters[60]. Research and Development - Research and development investments have increased by 40%, focusing on innovative pharmaceutical solutions[2]. - R&D expenses decreased by 12.79% to CNY 23.17 million, reflecting the company's focus on cost control amid revenue challenges[56]. - The company received the National Science and Technology Progress Award First Class for its project on key technology innovation in the edible fungus industry, highlighting its commitment to R&D[52]. - The company has established strategic collaborations with academic institutions to develop health products, including 12 new food items, with 3 successfully launched[52]. Sustainability and Environmental Commitment - The management highlighted a strong commitment to sustainability, with plans to reduce carbon emissions by 25% by 2025[2]. - The company has been recognized as a national green low-carbon factory in 2024, focusing on energy consumption management and promoting green transformation[84]. - The company has committed to quarterly monitoring of waste gas and wastewater emissions, all of which comply with national discharge standards[84]. - The company has established a monitoring plan for 2024, ensuring compliance with pollutant discharge standards through regular third-party testing of wastewater and waste gas[80]. Financial Position and Liquidity - The company has maintained a solid financial position, with a current ratio of 2.5, indicating strong liquidity[2]. - As of the end of the reporting period, the net assets attributable to shareholders of the listed company were approximately ¥2.21 billion, an increase of 1.68% from ¥2.17 billion at the end of the previous year[15]. - Total assets amounted to approximately ¥3.11 billion, a decrease of 2.13% from ¥3.17 billion at the end of the previous year[15]. - The company holds a 4.93% stake in Wuyi Commercial Bank, with an increase in investment value to 72,968,760.17 RMB, reflecting a change of 15,102,923.04 RMB during the period[66]. Product Development and Innovation - New product launches are expected to contribute an additional 10% to overall revenue in the upcoming quarters[2]. - The company has developed new Ganoderma strains, including "XianZhi No. 1," "XianZhi No. 2," and "XianZhi No. 3," which have passed provincial certification and exhibit strong resistance and high yield[38]. - The company has set up a Dendrobium germplasm resource bank and developed new strains such as "XianHua No. 1," "XianHua No. 2," and "XianHua No. 3," recognized for their high survival rates and yields[39]. - The company has established a full industry chain development model for products like Ganoderma and Dendrobium, ensuring quality from breeding to sales[35]. Risks and Challenges - There are no significant risks identified that could impact the company's operations in the near future[1]. - The company faces risks related to natural disasters affecting the supply of raw materials, particularly for its main products[68]. - The company is at risk of inventory turnover issues due to high-value products, which could impact its operational efficiency if not managed properly[75]. - The company faces risks related to the potential loss of breeding technology and genetic resources, which could weaken its competitive position and profitability[72]. Shareholder and Corporate Governance - The company did not propose any profit distribution or capital reserve increase for the current period, indicating a focus on reinvestment rather than immediate shareholder returns[78]. - The controlling shareholder has promised to avoid any preferential treatment in business cooperation with the company and its controlled enterprises, ensuring compliance with relevant laws and regulations since March 26, 2015[87]. - The company has committed to not engaging in any competitive activities with its subsidiaries and has adhered to this commitment since March 26, 2015[86]. - The actual controllers of the company, the Li Mingyan family, collectively hold 38.08% of the shares, with Li Mingyan and Zhu Huizhao being spouses, and Li Zhenhao and Li Zhenyu being brothers[105].

Group 1: Event Details - The investor reception day is scheduled for September 6, 2024, from 10:40 AM to 4:00 PM [2] - The event will take place at two locations: the company's organic health garden in the morning and the headquarters in the afternoon [2] - Key participants include the Chairman, Vice General Managers, and the Director of Investor Services [2] Group 2: Agenda - The agenda includes a visit to the organic health garden, lunch, and a tour of the biological breeding innovation laboratory [3][4] - Specific timings for each activity are outlined, with the first visit starting at 10:40 AM and concluding with investor discussions from 2:40 PM to 4:00 PM [3][4] Group 3: Registration and Requirements - Investors must register by September 4, 2024, at 3:00 PM, either through a QR code or by sending a registration form via email [4] - Participants are required to bring identification documents for verification [4] - A commitment letter must be signed by participants, ensuring confidentiality regarding undisclosed information [8] Group 4: Transportation and Costs - The company will provide transportation to the event locations and cover the cost of lunch [5] - Other expenses incurred by attendees will be their own responsibility [5]

| 证券代码：603896 | 证券简称：寿仙谷 | | 公告编号：2024-049 | | --- | --- | --- | --- | | 债券代码：113660 | 债券简称：寿 22 | 转债 | | 浙江寿仙谷医药股份有限公司 2024 年半年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据中国证券监督管理委员会（以下简称"中国证监会"）《上市公司监管指 引第 2 号——上市公司募集资金管理和使用的监管要求》、《上海证券交易所上市 公司自律监管指引第 1 号——规范运作》以及《上海证券交易所上市公司自律监 管指南第 1 号——公告格式》等有关规定，现将浙江寿仙谷医药股份有限公司 （以下简称"公司"或"寿仙谷"）2024 年半年度募集资金存放与使用情况专项说明 如下： 一、募集资金基本情况 （一）2020 年公开发行可转换公司债券募集资金 公司 2020 年度实际使用募集资金 1,177,000.00 元，累计收到银行存款利息 扣除手续费等的净额为 810,992.29 元 ...

债券代码：113660 债券简称：寿 22 转债 浙江寿仙谷医药股份有限公司 关于召开 2024 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | | | 重要内容提示： 浙江寿仙谷医药股份有限公司（以下简称"公司"或"寿仙谷"）于 2024 年 08 月 28 日发布公司 2024 年半年度报告，为便于广大投资者更全面深入地了 解公司 2024 年半年度经营成果、财务状况，公司计划于 2024 年 09 月 11 日下午 13:00-14:30 举行 2024 年半年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以视频结合网络互动召开，公司将针对 2024 年半年度经 营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的 范围内就投资者普遍关注的问题进行回答。 会议召开时间：2024 年 09 月 11 日（星期三） 下午 13:00-14:30 会议召开地点： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://ro ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 证券代码：603896 | 证券简称：寿仙谷 | | 公告编号：2024-047 | | --- | --- | --- | --- | | 债券代码：113660 | 债券简称：寿 22 | 转债 | | 浙江寿仙谷医药股份有限公司 第四届董事会第二十三次会议决议公告 表决结果：同意票 9 票，反对票 0 票，弃权票 0 票。 2、审议并通过《浙江寿仙谷医药股份有限公司 2024 年半年度募集资金存放 与实际使用情况的专项报告》 公司 2024 年半年度募集资金的存放与使用符合中国证监会《上市公司监管 指引第 2 号——上市公司募集资金管理和使用的监管要求》、《上海证券交易所上 市公司自律监管指引第 1 号——规范运作》等有关规定的要求，不存在变相改变 募集资金用途和违规使用募集资金的情形。公司已披露的相关信息及时、真实、 准确、完整地反映了募集资金使用情况，如实履行了信息披露义务。具体内容详 见公司同日披露的《寿仙谷 2024 年半年度募集资金存放与实际使用情况的专项 报 ...

浙江寿仙谷医药股份有限公司 第四届监事会第十三次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 浙江寿仙谷医药股份有限公司（以下简称"公司"或"寿仙谷"）第四届监 事会第十三次会议于 2024 年 8 月 27 日在公司会议室召开，会议通知于 2024 年 8 月 17 日以电子邮件形式发出，会议应到监事 3 名，实到监事 3 名，公司董事 会秘书列席了会议。本次会议由监事会主席徐凌艳女士主持，会议的召开符合《公 司法》及《公司章程》的有关规定。 二、监事会会议审议情况 1、审议并通过《浙江寿仙谷医药股份有限公司 2024 年半年度报告》（全文 及摘要） 公司监事会认为，公司 2024 年半年度报告系依据中国证监会《公开发行证 券的公司信息披露内容与格式准则第 3 号——半年度报告的内容与格式》、《上海 证券交易所股票上市规则》等有关规定编制，报告真实、准确、完整地反映了公 司的财务状况和经营成果，在报告编制和审议期间未发现内幕信息泄露的情况或 其他损害公司利益的行为。具体内容详见公司同日 ...

浙江寿仙谷医药股份有限公司 关于公司及全资子公司获得发明专利证书的公告 | 证券代码：603896 | 证券简称：寿仙谷 | | 公告编号：2024-046 | | --- | --- | --- | --- | | 债券代码：113660 | 债券简称：寿 22 | 转债 | | 授权公告号：CN 114438240 B 专利申请日：2021 年 12 月 31 日 授权公告日：2024 年 08 月 06 日 专利权期限：二十年（自申请日起算） 上述专利的取得不会对公司近期的生产经营产生重大影响，但体现了公司的 研发和创新能力，有利于公司进一步完善知识产权保护体系，发挥自主知识产权 优势，并形成持续创新机制，提升公司的核心竞争力。 特此公告。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，浙江寿仙谷医药股份有限公司（以下简称"公司"）及全资子公司浙 江寿仙谷植物药研究院有限公司收到了国家知识产权局颁发的发明专利证书。具 体情况如下： 证书号：第 7262498 号 发明名称：一种铁皮石斛高分辨率熔解曲线鉴别引物、应 ...

浙江寿仙谷医药股份有限公司 2024 年第一次临时股东大会决议公告 | 公告编号：2024-044 | | --- | | 证券简称：寿仙谷 | | 证券代码：603896 | 债券代码：113660 债券简称：寿 22 转债 资料于 2024 年 7 月 25 日发布，董事长李明焱先生主持会议，会议记录由董事会 秘书刘国芳女士负责。本次股东大会经浙江天册律师事务所黄丽芬律师和陈治铭 律师见证。会议的召集、召开及表决方式符合《中华人民共和国公司法》、中国 证券监督管理委员会《上市公司股东大会规则》、上海证券交易所《上市公司股 东大会网络投票实施细则》和《浙江寿仙谷医药股份有限公司章程》的有关规定。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 256 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 75,953,588 | | 3、出席会议的股东所持有表决权股份数占公司有表决权 ...